The antibody–drug conjugate trastuzumab deruxtecan could soon be the first therapy of its kind to be approved as a tumor-agnostic treatment for HER2-mutant or -expressing tumors. However, appropriate patient selection and adverse event management will be key to maximizing its benefit.

©2023 American Association for Cancer Research
2023
American Association for Cancer Research
You do not currently have access to this content.